🔗 Share this article WHO Sounds Concern Over Severe Shortage of Obesity Injections Less than a tenth of individuals who could benefit from obesity jabs like Wegovy have access to them, states the global health agency as it publishes its inaugural recommendations on the medications. Considering more than one billion people worldwide now obese, it is calling for broader and more equitable availability to GLP-1 medication. According to forecasts, over two billion could be living with obesity by 2030 unless action is taken. "Our new guidelines acknowledges that excess weight is a long-term condition that can be managed with thorough and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and supply-chain constraints are key hurdles to broad access to the treatments that can assist patients in reducing significant weight, explains the body. Skinny Jab Scarcity Even in the present best projected scenario, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of those who need them, per the health organization. The advice encourages nations and manufacturers to widen availability, via measures like voluntary licensing. A patent on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026. How Obesity Jabs Operate GLP-1 drugs imitate a body's own hormone to slow digestion, reduce hunger and boost satiety so people reduce food intake. Patients usually begin shedding pounds after several weeks of starting on the weekly injections. Evidence points to people may put most of the weight back on within a year of halting the treatment, when their usual food cravings resume. To be overweight or obese raises your chance for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Obesity affects people in every country and was responsible for millions of deaths worldwide in 2024, according to the WHO.
Less than a tenth of individuals who could benefit from obesity jabs like Wegovy have access to them, states the global health agency as it publishes its inaugural recommendations on the medications. Considering more than one billion people worldwide now obese, it is calling for broader and more equitable availability to GLP-1 medication. According to forecasts, over two billion could be living with obesity by 2030 unless action is taken. "Our new guidelines acknowledges that excess weight is a long-term condition that can be managed with thorough and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and supply-chain constraints are key hurdles to broad access to the treatments that can assist patients in reducing significant weight, explains the body. Skinny Jab Scarcity Even in the present best projected scenario, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of those who need them, per the health organization. The advice encourages nations and manufacturers to widen availability, via measures like voluntary licensing. A patent on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026. How Obesity Jabs Operate GLP-1 drugs imitate a body's own hormone to slow digestion, reduce hunger and boost satiety so people reduce food intake. Patients usually begin shedding pounds after several weeks of starting on the weekly injections. Evidence points to people may put most of the weight back on within a year of halting the treatment, when their usual food cravings resume. To be overweight or obese raises your chance for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Obesity affects people in every country and was responsible for millions of deaths worldwide in 2024, according to the WHO.